for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Bayer's Finerenone Meets Primary Endpoint In Phase Iii Fidelio-Dkd Renal Outcomes Study

July 9 (Reuters) - Bayer AG:

* BAYER’S FINERENONE MEETS PRIMARY ENDPOINT IN PHASE III FIDELIO-DKD RENAL OUTCOMES STUDY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES

* BAYER - FINERENONE REDUCED COMBINED PRIMARY ENDPOINT OF RISK OF CHRONIC KIDNEY DISEASE PROGRESSION, KIDNEY FAILURE/KIDNEY DEATH VERSUS PLACEBO WHEN ADDED TO STANDARD OF CARE Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up